Daiichi Life's Australian Arm Proposes to Buy the Rest of Challenger at A$11.80 a Share in a Non-Binding Offer

A Japanese-owned life insurer in Australia has made an approach to buy out one of the country's best-known annuity providers. Reinsurance News reported on October 22, 2026 that TAL Daiichi Life Australia Pty Limited, known as TDA and a subsidiary of Daiichi Life Group, has submitted a "non-binding indicative proposal" to the board of Challenger. The proposal would see TDA acquire the remaining 79.5% of Challenger's ordinary shares for A$11.80 per share, implemented through a scheme of arrangement.

A scheme of arrangement is a court-approved procedure commonly used for takeovers in Australia and the United Kingdom. Shareholders vote on the deal, and if enough support it and the court approves, the transfer binds all shareholders. It requires cooperation from the target's board, which is why an initial approach is usually made privately and described as an indicative proposal. "Non-binding" means neither side is committed: Challenger's board could reject it, negotiate a higher price or agree to engage.

The source, as available for this article, leaves out several details that matter. It does not state the premium that A$11.80 represents over Challenger's recent share price, so it is not possible to say how generous the offer is. It does not disclose an overall valuation, and it does not directly state how many Challenger shares TDA already owns. The reference to the "remaining 79.5%" implies TDA holds about 20.5%, but that is an inference from the arithmetic, not a statement in the report. No quote from executives or from Challenger's board is included, and the board's response has not been reported.

The proposal is conditional on three things: satisfactory exclusive due diligence, agreement of final terms, and all necessary regulatory approvals. Due diligence means TDA would examine Challenger's books in detail, and "exclusive" suggests it would ask for a period in which Challenger does not negotiate with others. Regulatory approvals in a deal like this would typically involve Australian authorities that supervise insurers and review foreign investment, but the source does not name them, and no timetable is given.

There is a history behind the approach. In April 2025, MS&AD Insurance Holdings, the Japanese non-life insurer, agreed to sell about 104,353,125 Challenger shares, equal to 15.1% of the company, to TDA for 80 billion yen. That transaction put the Daiichi subsidiary in a significant minority position. The 15.1% stake and the 79.5% remaining suggest that TDA holds roughly a fifth of Challenger after that and any earlier purchases, though, again, the exact current holding is not stated in the report.

Why would Daiichi Life want Challenger? The source does not give reasons, so the following is context and not reporting. Challenger specialises in annuities, products that convert a lump sum into a guaranteed income stream, and Australia has a large pool of retirement savings in its superannuation system, with a growing number of people moving from saving to spending in retirement. The Australian prudential regulator recently changed the capital rules for longevity products to make them easier to offer, so the market for lifetime income products is attracting attention. A Japanese life insurer with experience of an ageing society may see Australia as a market with similar needs.

The proposal also continues a pattern of Japanese life insurers expanding abroad. Sumitomo Life has set aside up to ¥1 trillion for deals in the United States and Southeast Asia, Meiji Yasuda completed its purchase of Legal & General's US business in February 2026, and Nippon Life has built stakes in Corebridge and Resolution Life. Daiichi, which has owned Protective Life in the United States since 2015, has been active in Australia through TAL. Fitch's recent review of Japanese insurers notes that overseas operations are a major source of earnings for the large groups.

What happens next? If Challenger's board is willing, it could grant TDA due diligence, and the parties could negotiate a binding scheme implementation deed, which would be announced with details of price, conditions and timetable. The board could also reject the proposal, in which case TDA could raise its offer, hold its stake or make a direct approach to shareholders, although none of these outcomes is reported. Shareholders, including large institutions, would need to vote, and the scheme would require approval by the court. Regulators would also need to review the effect on policyholders and on the stability of the annuity market.

For Challenger's annuity customers, nothing changes now. Their policies are contracts with Challenger's life company and remain in force whatever happens to the share register. A change of control, if it occurs, would be subject to regulatory review, which would consider the financial strength of the new owner and the protection of policyholders.

Readers should treat the report with caution. It is based on a single short announcement, with no price premium, valuation or board comment, and the proposal is explicitly non-binding. Many indicative proposals do not result in a completed deal. The key facts to watch are Challenger's response, any disclosure of TDA's current holding and any change in the price or terms.